Results of this study will inform development of interventions to help mitigate barriers to HCT, focusing on areas of Virginia that may benefit most. Please direct questions regarding support opportunities at the 2021 TCT Meetings of ASTCT & CIBMTR to the TCT Meetings Conference Office: [email protected]. Together, these three organizations support all BMT CTN activities. Are we giving sufficient priority to studies that gain deeper insights about the contributors to poor access to inform policy advocacy and make positive change? Certainly, each of our centers have unique challenges—and opportunities for progress. In the meantime, in the midst of the continued uncertainty, we hope that you, your families, and your patients stay safe and healthy. The CIBMTR shares administration of the BMT CTN Data and Coordinating Center with NMDP/Be The Match and The Emmes Company. The committee's studies also include comparisons of clinical outcomes from different donor types (e.g., mismatched related versus unrelated donors) and exploration of novel biostatistical and analytic approaches to investigate the impact of various HLA mismatches. The CIBMTR recently announced seven Pilot Partner Sites readying to test new methods of sending data electronically to the CIBMTR with the goal of reducing the administrative burden for centers to submit their data to the CIBMTR. Far too many do not get to transplant at my center. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database. Working committee meetings convene annually at the TCT Meetings of ASTCT & CIBMTR, although other venues for interaction are also available. Just when we thought things could not get worse, they did. ), Pre-Transplant Essential Data: Disease Classification, RETIRED Selective Post-Transplant Essential Data, Intravenous Busulfan Study — Supplemental Data, Tepadina® Supplemental Data Collection Form, Inotuzumab Ozogamicin Supplemental Data Collection Form, Myelofibrosis CMS Study Pre-HCT Supplimental Form, Myelofibrosis CMS Study Post-HCT Supplimental Form, Sanofi Mozobil Supplemental Data Collection, Cellular Therapies for Regenerative Medicine, Cellular Therapy Essential Data Follow-Up Form, Insert XXXIX - Congenital Amegakaryocytic Thrombocytopenia, Follow-up Insert XXXIX - Congenital Amegakaryocytic Thrombocytopenia, DCI Supplement Insert - Chronic Lymphocytic Leukemia, DCI Supplement Insert - Juvenile Myelomonocytic Leukemia (JMML or JCML), DCI Supplement Insert - Langerhans Cell Histiocytosis (LCH), DCI Supplement Insert - Hodgkin and Non-Hodgkin Lymphoma, DCI Supplement Insert - Waldenstrom’s Macroglobulinemia, DCI Supplement Insert - Multiple Myeloma/Plasma Cell Leukemia, DCI Supplement Insert - Testicular Cancer/Germ Cell Tumors, Follow-up Insert XXXVI - Renal Carcinoma, Insert XXXVII - X-Linked Lymphoproliferative Syndrome, Follow-up Insert XXXVII - X-Linked Lymphoproliferative Syndrome, Follow-up Insert II - Acute Lymphoblastic Leukemia, Follow-up Insert I - Acute Myelogenous Leukemia, Follow-up Insert XIX - Chediak-Higashi Syndrome, Follow-up Insert IV - Chronic lymphocytic leukemia, Insert III - Chronic Myelogenous Leukemia, Follow-up Insert III - Chronic Myelogenous Leukemia, Insert XVIII - Central Nervous System Tumor, Follow-up Insert XVIII - Central Nervous System Tumor, Insert X - Fanconi Anemia/Constitutional Anemia, Fllow-up Insert X - Fanconi Anemia/Constitutional Anemia, Insert XXXIII - Juvenile Myelomonocytic Leukemia (JMML or JCML), Follow-up Insert XXXIII - Juvenile Myelomonocytic Leukemia (JMML or JCML), Insert XXVIII - Juvenile Idiopathic Arthritis (JIA) (Previously JRA or JCA), Follow-up Insert XXVIII - Juvenile Idiopathic Arthritis (JIA) (Previously JRA or JCA), Insert XXVII - Langerhans Cell Histiocytosis, Follow-up Insert XXVII - Langerhans Cell Histiocytosis, Insert VI - Hodgkin and Non-Hodgkin Lymphoma, Follow-up Insert VI - Hodgkin and Non-Hodgkin Lymphoma, Insert XXVI - Waldenstrom’s Macroglobulinemia, Follow-up Insert XXVI - Waldenstrom’s Macroglobulinemia, Insert V - Myelodysplasia/Myeloproliferative Disorders, Follow-up Insert V - Myelodysplasia/Myeloproliferative Disorders, Follow-up Insert XXI - Multiple Sclerosis, Insert XXXIV Mucopolysaccharidosis and Other Storage Diseases, Follow-up Insert XXXIV Mucopolysaccharidosis and Other Storage Diseases, Insert VII - Multiple Myeloma/Plasma Cell Leukemia, Follow-up Insert VII - Multiple Myeloma/Plasma Cell Leukemia, Follow-up Insert XXII - Rheumatoid Arthritis, Follow-up Insert XX - Small Cell Lung Cancer, Insert XXIII -Systemic Lupus Erythematosus, Follow-up Insert XXIII -Systemic Lupus Erythematosus, Follow-up Insert XXIV - Systemic Sclerosis, Follow-up Insert XXXII - Testicular Cancer, Follow-up Insert XIII -Wiskott-Aldrich Syndrome, Transplant Essential Data - Modified 100 Day Report for Preregistered Patients, Transplant Essential Data First Report: 100 Days Post Transplant, Transplant Essential Data Follow-up Report - 1 Year Post Transplant and Annually, Recipient Baseline and Transplant Data Insert I - Acute Myelogenous Leukemia, Recipient Baseline and Transplant Data Insert II - Acute Lymphoblastic Leukemia, Recipient Baseline and Transplant Data Insert III - Chronic Myelogenous Leukemia, Recipient Baseline and Transplant Data Insert IV - Other Leukemias, Recipient Baseline and Transplant Data Insert IX - Hodgkin and Non-Hodgkin Lymphoma, Recipient Baseline and Transplant Data Insert V - Myelodysplasia/Myeloproliferative Disorders, Recipient Baseline and Transplant Data Insert VI - Multiple Myeloma, Recipient Baseline and Transplant Data Insert VII - Other Malignancy, Recipient Baseline and Transplant Data Insert VIII - Aplastic Anemia, Recipient Baseline and Transplant Data Insert X - Severe Combined Immunodeficiency, Recipient Baseline and Transplant Data Insert XI - Wiskott Aldrich Syndrome, Recipient Baseline and Transplant Data Insert XIII - Leukodystrophies, Recipient Baseline and Transplant Data Insert XIV - Mucopolysaccharidoses and Other Storage Diseases, Recipient Baseline and Transplant Data Insert XV - Chediak-Higashi Syndrome, Recipient Baseline and Transplant Data Insert XVI - Hemophagocytic Lymphohistiocytosis, Recipient Baseline and Transplant Data Insert XVII - X-Linked Lymphoproliferative Disease, Recipient Baseline and Transplant Data Insert XVIII - Renal Carcinoma, Insert V – Leukodystrophies 100-day Follow-up Visit of Recipient, Insert VI – Mucopolysaccharidoses 100-day Follow-up Visit of Recipient, Post-Transplant Follow-up Form Insert I – Severe Combined Immunodeficiency, Post-Transplant Follow-up Form Insert II – Wiscott Aldrich Syndrome, Insert IX – Hemphagocytic Lymphohistiocytosis Post-Transplant Follow-up Form, Insert VIII – Chediak-Higashi Syndrome Post-Transplant Follow-Up Form, Insert X – X-linked Lymphoproliferative Disease Post-Transplant Follow-Up Form, Post-Transplant Follow-up Form Insert XI – Renal Carcinoma, Insert III – Post-Transplant Information for Hodgkin and Non-Hodgkin Lymphoma, Six Month to Two Year Follow-Up Visit of Recipient, Insert V – Leukodystrophies Annual Follow-up Visit of Recipient, Insert VI – Mucopolysaccharidoses Annual Follow-up Visit of Recipient, Yearly Follow-Up for Greater Than Two Years Post-Transplant, Filgrastim Mobilized Peripheral Blood Stem Cells (PBSC) Transplant Center PBSC Product Analysis.